Avoiding Undertreatment, Overtreatment in Geriatric Breast Cancer Patients
This video reviews how to ensure that older breast cancer patients are receiving the most appropriate care and highlights population studies that can help inform individual treatment decisions.
A paradox exists in the treatment of older breast cancer patients. This population has a higher risk of dying from their breast cancer and in many cases patients are being undertreated, as some can safely receive more effective treatments based on their specific disease characteristics.
But older patients also have a higher risk of dying from other causes compared with younger populations, and the risk of overtreatment is a serious consideration.
In this video, Hans Wildiers, MD, PhD, of University Hospitals Leuven in Belgium, discusses how to ensure that these patients are receiving the most appropriate care and highlights population studies that can help inform individual treatment decisions.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
